MR imaging of the substantia nigra at 7 T enables diagnosis of parkinson disease

Radiology

Volumn 271, Issue 3, 2014, Pages 831-838

  Cosottini, Mirco ^a,b   Frosini, Daniela ^c   Pesaresi, Ilaria ^d   Costagli, Mauro ^a   Biagi, Laura ^e   Ceravolo, Roberto ^c   Bonuccelli, Ubaldo ^c   Tosetti, Michela ^e  

^a IMAGO7 Foundation   (Italy)

^b Department of Translational Research and New Surgical and Medical Technologies ^*  (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

^e DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CEREBRAL PEDUNCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EX VIVO STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; MALE; MESENCEPHALON; MORPHOLOGY; NEUROANATOMY; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PARS COMPACTA DORSALIS; PARS COMPACTA VENTRALIS; PATHOLOGICAL ANATOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STRUCTURE ANALYSIS; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS RETICULATA; SUSCEPTIBILITY WEIGHTED IMAGING; THALAMUS INTRALAMINAR NUCLEUS; THREE DIMENSIONAL IMAGING; THREE DIMENSIONAL MULTIECHO SUSCEPTIBILITY WEIGHTED IMAGING;

ADULT; AGED; CADAVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA;

EID: 84901660642     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14131448     Document Type: Article

References (38)

1. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283-2301.
2. Lehéricy S, Sharman MA, Dos Santos CL, Paquin R, Gallea C. Magnetic resonance imaging of the substantia nigra in Parkinson's disease. Mov Disord 2012;27(7): 822-830.
3. Brooks DJ. Parkinson's disease: diagnosis. Parkinsonism Relat Disord 2012;18(Suppl 1):S31-S33.
4. Hutchinson M, Raff U, Lebedev S. MRI correlates of pathology in parkinsonism: segmented inversion recovery ratio imaging (SIRRIM). Neuroimage 2003;20(3):1899-1902.
5. Minati L, Grisoli M, Carella F, De Sim-one T, Bruzzone MG, Savoiardo M. Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. AJNR Am J Neuroradiol 2007;28(2):309-313.
6. Oikawa H, Sasaki M, Tamakawa Y, Ehara S, Tohyama K. The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR fndings. AJNR Am J Neuroradiol 2002;23(10):1747- 1756.
7. Ordidge RJ, Gorell JM, Deniau JC, Knight RA, Helpern JA. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Re-son Med 1994;32(3):335-341.
8. Graham JM, Paley MN, Grünewald RA, Hoggard N, Griffths PD. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000;123(Pt 12):2423-2431.
9. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008;70(16 Pt 2):1411-1417.
10. Péran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010;133(11):3423-3433.
11. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72(16):1378-1384.
12. Du G, Lewis MM, Styner M, et al. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 2011;26(9):1627-1632.
13. Menke RA, Jbabdi S, Miller KL, Matthews PM, Zarei M. Connectivity-based segmentation of the substantia nigra in human and its implications in Parkinson's disease. Neuro-image 2010;52(4):1175-1180.
14. Eckert T, Sailer M, Kaufmann J, et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 2004;21(1):229-235.
15. Helms G, Draganski B, Frackowiak R, Ash-burner J, Weiskopf N. Improved segmentation of deep brain grey matter structures using magnetization transfer (MT) parameter maps. Neuroimage 2009;47(1):194-198.
16. Sasaki M, Shibata E, Tohyama K, et al. Neu-romelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006;17(11): 1215-1218.
17. Ogisu K, Kudo K, Sasaki M, et al. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars com-pacta for diagnosis of Parkinson's disease. Neuroradiology 2013;55(6):719-724.
18. Cho ZH. New brain atlas-Mapping the human brain in vivo with 7.0 T MRI and comparison with postmortem histology: Will these images change modern medicine? Int J Imaging Syst Technol 2008;18(1): 2-8.
19. Costagli M, Frosini D, Pesaresi I, et al. Multi-parametric MR imaging of the sub-stantia nigra at 7.0T to investigate Parkinson's Disease [abstr]. In: Proceedings of the Twenty-First Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2013.
20. Cho ZH, Oh SH, Kim JM, et al. Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging. Mov Disord 2011;26(4):713-718.
21. Eapen M, Zald DH, Gatenby JC, Ding Z, Gore JC. Using high-resolution MR imaging at 7T to evaluate the anatomy of the mid-brain dopaminergic system. AJNR Am J Neuroradiol 2011;32(4):688-694.
22. Lotfpour AK, Wharton S, Schwarz ST, et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging 2012;35(1): 48-55.
23. Kwon DH, Kim JM, Oh SH, et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012;71(2):267-277.
24. Naidich TP, Duvernoy HM, Delman BN, So-rensen AG, Kollias SS, Haacke EM. Duver-noy's atlas of the human brain stem and cerebellum. Vienna, Austria: Springer-Verlag, 2009.
25. Halliday G, Reyes S, Double K. Substantia nigra, ventral tegmental area, and retroru-bral felds. In: Mai JK, Paxinos G eds. The human nervous system. 3rd ed. London: Elsevier Academic Press, 2012; 439-455.
26. Nieuwenhuys R, Voogd J, van Huijzen C. The human central nervous system: a synopsis and atlas. 4th rev ed. New York, NY: Springer, 2007.
27. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51(6):745-752.
28. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17(5):427-442.
29. Fahn S, Elton RL; members of the UPDRS Development Committee. Unifed Parkinson's disease rating scale. In: Fahn D, Mars-den CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information, 1987.
30. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159-174.
31. Massey LA, Yousry TA. Anatomy of the sub-stantia nigra and subthalamic nucleus on MR imaging. Neuroimaging Clin N Am 2010; 20(1):7-27.
32. Hassler R. Zur Normalanatomie der Sub-stantia nigra. Versuch einer architektonischen Gliederung. J Psychol Neurol 1937;48(1-2):1-55.
33. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a com-partmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999; 122(Pt 8):1421-1436.
34. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-contain-ing neurons in Parkinson's disease. Brain 1999;122(Pt 8):1437-1448.
35. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54(5):388-396.
36. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995;45(6): 1138-1143.
37. Sofc E, Paulus W, Jellinger K, Riederer P, Youdim MB. Selective increase of iron in substantia nigra zona compacta of parkin-sonian brains. J Neurochem 1991;56(3): 978-982.
38. Rutledge JN, Hilal SK, Silver AJ, Defendini R, Fahn S. Study of movement disorders and brain iron by MR. AJR Am J Roentgenol 1987;149(2):365-379.